Cartesian Therapeutics Future Growth
Future criteria checks 1/6
Cartesian Therapeutics is forecast to grow earnings and revenue by 16% and 12.9% per annum respectively while EPS is expected to grow by 82.4% per annum.
Key information
13.8%
Earnings growth rate
83.7%
EPS growth rate
Biotechs earnings growth | 24.1% |
Revenue growth rate | 12.9% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 03 Jul 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 14 | -91 | -80 | -21 | 5 |
12/31/2025 | 12 | -68 | -61 | -18 | 6 |
12/31/2024 | 16 | -94 | -62 | 78 | 7 |
3/31/2024 | 26 | -292 | -59 | -58 | N/A |
12/31/2023 | 26 | -257 | -51 | -51 | N/A |
9/30/2023 | 0 | -9 | -8 | -8 | N/A |
12/31/2022 | 111 | 35 | -33 | -32 | N/A |
12/31/2021 | 85 | -26 | -61 | -60 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RNAC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RNAC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RNAC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RNAC's revenue (12.9% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: RNAC's revenue (12.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RNAC's Return on Equity is forecast to be high in 3 years time